Allergan Inc. announced that the U.S. Food and Drug Administration (FDA) General and Plastic Surgery Devices Panel of the Medical Devices Advisory Committee has voted unanimously that the benefits of JUVÉDERM VOLUMA(TM) XC, an injectable hyaluronic acid dermal filler for cheek augmentation to correct age-related volume deficit in the mid-face, outweigh the risks. If approved, JUVÉDERM VOLUMA(TM) XC would be the first and only dermal filler in the United States with this indication. The Advisory Committee's recommendation, although not binding, will be considered by the FDA when making the final approval decision for JUVÉDERM VOLUMA(TM) XC. If approved by the FDA, Allergan anticipates launching JUVÉDERM VOLUMA(TM) XC in late 2013.

Allergan Inc. announced unaudited consolidated earnings results for the first quarter ended March 31, 2013. For the quarter ended March 31, 2013, the company reported $0.89 diluted earnings per share attributable to stockholders compared to $0.74 diluted earnings per share attributable to stockholders for the first quarter of 2012. The company reported $0.98 non-GAAP diluted earnings per share attributable to stockholders compared to $0.83 non-GAAP diluted earnings per share attributable to stockholders for the first quarter of 2012, an 18.1% increase. On GAAP basis, the company's revenue was $1,459.6 million, compared to $1,347.9 million for the last year. Operating income was $371.1 million, compared to $351.8 million for the last year. Earnings from continuing operations before income taxes were $371.1 million, compared to $351.8 million for the last year. Earnings from continuing operations were $273.0 million, compared to $228.4 million for the last year. Net earnings attributable to the company were $12.5 million, compared to $229.8 million for the last year. On non-GAAP basis, the company's operating income was $427.3 million, compared to $378.4 million for the last year. Earnings from continuing operations before income taxes were $405.3 million, compared to $361.3 million for the last year. Earnings from continuing operations were $298.1 million, compared to $258.1 million for the last year. Net earnings attributable to the company were $296.2 million, compared to $257.6 million for the last year. For the second quarter of 2013, the company expects total product net sales between $1,500 million and $1,575 million, which exclude the obesity intervention business. Non-GAAP diluted earnings per share attributable to stockholders from continuing operations between $1.18 and $1.20, which includes the dilutive impact of the acquisition of MAP Pharmaceuticals. GAAP diluted earnings per share attributable to the stockholders from continuing operations expects to be in the range of $1.12 - $1.14. For the full year of 2013, the company expects total product net sales between $5,975 million and $6,200 million, which exclude the obesity intervention business. Non-GAAP amortization of intangible assets was approximately $10 million. This expectation excludes the amortization of certain intangible assets associated with business combinations, asset purchases and product licenses. Non-GAAP diluted earnings per share attributable to stockholders from continuing operations between $4.70 and $4.76, which includes the dilutive impact of the acquisition of MAP Pharmaceuticals, and excludes the 2012 impact of the Research and Development tax credit, which was signed into law on January 2, 2013 and retroactively reinstated to January 1, 2012. Effective tax rate on non-GAAP earnings from continuing operations was between 26% and 27%. GAAP diluted earnings per share attributable to the stockholders from continuing operations expects to be in the range of $4.43 - $4.49. In the first quarter of 2013, the company also reported a separate non-cash pre-tax disposal loss of $346.2 million ($259.0 million after tax) from the write-down of the net assets held for sale to their estimated fair value less costs to sell. Impairment of a non-marketable equity investment was $3.7 million.

Allergan Inc. announced that Stephen J. Ryan, M.D., a member of the company Board of Directors, died on April 29, 2013 after a short illness.